Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com
HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

AI concept of cancer vaccine | Image credit: radekcho - stock.adobe.com
February 5th 2025

Promising Cancer Vaccine Boosts Hope for Stage III and IV Kidney Cancer

Pearl Steinzor
All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.
COA Offers “Prescription” for Tackling Rising Costs, Loss of Patient Access in Cancer Care and Beyond
February 5th 2025

COA Offers “Prescription” for Tackling Rising Costs, Loss of Patient Access in Cancer Care and Beyond

Mary Caffrey
The 5-part plan focuses on issues that have been calling cards for the Community Oncology Alliance (COA) in recent years, which gained traction in the last Congress and show up regularly on lists of the most pressing problems in health care.
Debra Patt, MD, PhD, MBA, MPH
February 4th 2025

Dr Debra Patt Pushes for PBM Reform and Physician Reimbursement Fixes

Mary Caffrey Debra Patt, MD, PhD, MBA, MPH
Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.
Older patient exercising | image credit: MAGIC - stock.adobe.com
February 4th 2025

New Findings Strengthen Case for Exercise Therapy in Cancer Care

Kyle Munz
A new meta-analysis adds to the body of literature promoting the benefits of exercise for patients with cancer.
Oscar B. Lahoud, MD, and Kasey Bond, MPH
February 4th 2025

Addressing Cancer Care Barriers Through Community Outreach and Support

Maggie L. Shaw Oscar B. Lahoud, MD Kasey Bond, MPH
February 4 is World Cancer Day, and in these interviews with our Strategic Alliance Partner, NYU Langone Health, we learn about the importance of forming strong relationships with the communities you are located in and with whom you work to optimize cancer-related outcomes.
Oncology Research | Image credit: iStock
January 30th 2025

Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event

Mary Caffrey
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
FDA Approval | Image credit: wladimir1804 - stock.adobe.com
January 29th 2025

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

Ashling Wahner
Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.
Chelsee Jensen, PharmD, BCPS.
January 29th 2025

Optimizing Oncology Drug Use While Mitigating Shortages

Cameron Santoro Chelsee J. Jensen, PharmD, BCPS
Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient and system costs by optimizing the use of generics and biosimilars, which offer lower costs without compromising safety and efficacy.
Kirollos Hanna, PharmD
January 28th 2025

Balancing Longevity, Quality, and Cost in Oncology Care

Kyle Munz Kirollos Hanna, PharmD
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.
Female hands pointing at map | Image Credit: undrey - stock.adobe.com
January 27th 2025

Historical Redlining Increases Mortality Risk Among Young Patients With Cancer

Brooke McCormick
Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, demonstrating that structural racism contributes to disparities in survival outcomes.
Edgardo S. Santos Castillero, MD, FACP, FASCO | Image credit: TOI
January 25th 2025

Zongertinib Offers “The Best Toxicity Profile I Have Ever Seen,” Santos Says

Edgardo S. Santos Castillero, MD, FACP, FASCO Interview by Mary Caffrey
Flatiron Health, DeepScribe Unveil Partnership to Provide Oncology-Specific Ambient AI
January 22nd 2025

Flatiron Health, DeepScribe Unveil Partnership to Provide Oncology-Specific Ambient AI

Mary Caffrey
DeepScribe's technology aims to free doctors to focus on the patient visit.
AJMC
January 20th 2025

Effects of Individualized Nurse-Led Care Plans on Olaparib Treatment Duration

Denise Tran, PharmD Haesuk Park, PhD Jordon Rabey, MS Seth Killion, BS S. Bobby Arelli, MD Elaine Murphy, BS Yoona Kim, PharmD, PhD
A nurse-led personalized care program conducted through a specialty pharmacy prolonged medication persistence among patients with cancer receiving olaparib.
The new guideline is the NCCN’s first patient resource on the topic of cancer genetics and hereditary cancer risk. | Image credit: Connect world - stock.adobe.com
January 16th 2025

NCCN Publishes Patient Guidance on Genetic Testing for Cancer Risk

Rose McNulty
A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and testing for inherited genetic mutations linked with increased cancer risk.
Patient receiving lung cancer screening results | Image Credit: Nattakorn - stock.adobe.com
January 13th 2025

Lung Cancer Screening Facilities Least Accessible to American Indian/Alaska Native Patients, Rural Communities

Brooke McCormick
Some populations face significant disparities in accessing lung cancer screening facilities, with American Indian/Alaska Native (AI/AN)-majority and rural census tracts facing the greatest travel distances.
Child standing on scale | Image Credit: Protsenko Dmitriy - stock.adobe.com
January 13th 2025

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

Brooke McCormick
Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Houston, TX | Image credit: Kovacs – stock.adobe.com
January 7th 2025

Decisions and Precision in Value-Based Cancer Care

Hayden E. Klein
An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
FDA approved. | Image Credit: Pawel - stock.adobe.com .jpeg
January 2nd 2025

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

Pearl Steinzor
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
gastric cancer | Image credit: Crystal light - stock.adobe.com
January 2nd 2025

FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers

Skylar Jeremias
Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Highlights From ACCC Fall 2024
January 1st 2025

ICYMI: Highlights From ACCC Fall 2024

Pearl Steinzor
Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.
Top 5 Most-Read Oncology Articles of 2024
December 25th 2024

Top 5 Most-Read Oncology Content of 2024

Pearl Steinzor
This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!
Most Popular Articles of 2024 in Evidence-Based Oncology
December 23rd 2024

Most Popular Articles of 2024 in Evidence-Based Oncology

Mary Caffrey
Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.
Highlights From ASCO 2024
December 21st 2024

ICYMI: Highlights From ASCO 2024

Pearl Steinzor
Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.
chemotherapy | Image credit: Penn Medicine
December 19th 2024

The High Cost of Shortages of Low-Cost Chemotherapy

Interview by Mary Caffrey
Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com
December 17th 2024

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

Pearl Steinzor
Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).
FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com
December 16th 2024

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Kristi Rosa
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
Highlights From COA 2024
December 14th 2024

ICYMI: Highlights From COA 2024

Pearl Steinzor
The Community Oncology Alliance (COA) meetings featured expert discussions around the evolving landscape of oncology care and health care reform.
AJMC
December 13th 2024

Cost-Effectiveness of a Multicancer Early Detection Test in the US

Anuraag R. Kansal, PhD Ali Tafazzoli, PhD Alissa Shaul, MPH Ameya Chavan, MS Weicheng Ye, MPH Denise Zou, MA A. Mark Fendrick, MD
Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening.
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
December 12th 2024

Improving Access to Nivolumab by Lowering Age Restrictions in Clinical Trial

Pearl Steinzor
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program, member of the Lymphoma Research Foundation’s Scientific Advisory Board, shares findings on innovative strategies to improve access to new therapies in pediatric cancer.
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health
December 10th 2024

How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL

Pearl Steinzor
Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).
<12345678
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo